{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:17:58Z","timestamp":1783448278077,"version":"3.55.0"},"reference-count":29,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":424,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Prostate cancer growth is dependent upon androgens and hence therapies often target this signalling axis. These therapies, for example the antiandrogen enzalutamide, are successful in the majority of men; however, resistance is inevitable and the tumour progresses to the castrate-resistant stage, a disease of unmet clinical need. Consequently, there is a great need for novel therapeutics for castrate-resistant prostate cancer. Thieno[2,3-b]pyridine compounds have shown promise as novel anti-cancer molecules, but little is known about their efficacy in prostate cancer. To address this, a panel of thieno[2,3-b]pyridine compounds was screened to identify those with cytostatic\/cytotoxic activity in prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effect of the compounds upon prostate cancer proliferation and motility was assessed in a panel of cell lines representing different stages of the disease and non-tumorigenic controls. The effect of the compounds upon cell morphology and cell death was assessed using imaging and flow cytometry, respectively. The efficacy of the lead compound was also assessed in a patient-derived explant model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The compounds were found to inhibit prostate cancer proliferation and motility, promote G2\/M arrest, multinucleation and apoptosis. Importantly, treatment of patient-derived explants with the lead compound DJ160 demonstrated that the molecule inhibits prostate cancer proliferation, even in samples that appear to be resistant to enzalutamide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Thieno[2,3-b]pyridines therefore represent a potential therapy for prostate cancer, even when current therapies have failed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-24-0082","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:39:50Z","timestamp":1750685990000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Thieno[2,3-\n                    <i>b<\/i>\n                    ]pyridine compounds potently inhibit prostate cancer growth and motility"],"prefix":"10.1530","volume":"5","author":[{"given":"M A","family":"Alkheilewi","sequence":"first","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-9826","authenticated-orcid":true,"given":"D A","family":"Leach","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London 2 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mohr","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Zwacka","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Laissue","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Metodiev","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":true,"given":"C L","family":"Bevan","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London 2 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Van Rensburg","sequence":"additional","affiliation":[{"name":"School of Chemical Sciences, University of Auckland 3 , ,","place":["Auckland, New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L I","family":"Pilkington","sequence":"additional","affiliation":[{"name":"School of Chemical Sciences, University of Auckland 3 , ,","place":["Auckland, New Zealand"]},{"name":"Te Punaha Matatini 4 , ,","place":["Auckland, New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-6552","authenticated-orcid":true,"given":"D","family":"Barker","sequence":"additional","affiliation":[{"name":"School of Chemical Sciences, University of Auckland 3 , ,","place":["Auckland, New Zealand"]},{"name":"Te Punaha Matatini 4 , ,","place":["Auckland, New Zealand"]},{"name":"MacDiarmid Institute for Advanced Materials and Nanotechnology 5 , ,","place":["Wellington, New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Reynisson","sequence":"additional","affiliation":[{"name":"School of Allied Health Professions and Pharmacy, Keele University 6 , ,","place":["Keele, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-4134","authenticated-orcid":true,"given":"G N","family":"Brooke","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Essex 1 , ,","place":["Colchester, UK"]},{"name":"Department of Surgery and Cancer, Imperial College London 2 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2026070713311404900_bib2","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1039\/C5MD00245A","article-title":"A synthesis, in silico, in vitro and in vivo study of thieno[2,3-b]pyridine anticancer analogues","volume":"6","author":"Arabshahi","year":"2015","journal-title":"Medchemcomm"},{"key":"2026070713311404900_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/138920209787581307","article-title":"The role of androgen receptor mutations in prostate cancer progression","volume":"10","author":"Brooke","year":"2009","journal-title":"Curr Genomics"},{"key":"2026070713311404900_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1158\/0008-5472.CAN-10-0874","article-title":"FUS\/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth","volume":"71","author":"Brooke","year":"2011","journal-title":"Cancer Res"},{"key":"2026070713311404900_bib5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/1878-0261.12354","article-title":"A patient-derived explant (PDE) model of hormone-dependent cancer","volume":"12","author":"Centenera","year":"2018","journal-title":"Mol Oncol"},{"key":"2026070713311404900_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.137","article-title":"Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer","volume":"5","author":"Dai","year":"2014","journal-title":"Cell Death Dis"},{"key":"2026070713311404900_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bmc.2016.11.041","article-title":"3-Amino-thieno[2,3-b]pyridines as microtubule-destabilising agents: molecular modelling and biological evaluation in the sea urchin embryo and human cancer cells","volume":"25","author":"Eurtivong","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"2026070713311404900_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/EBC20190016","article-title":"Microtubules in cell migration","volume":"63","author":"Garcin","year":"2019","journal-title":"Essays Biochem"},{"key":"2026070713311404900_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116092","article-title":"Improving the solubility of anti-proliferative thieno[2,3-b]quinoline-2-carboxamides","volume":"37","author":"Haverkate","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"2026070713311404900_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejmech.2014.09.001","article-title":"Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives","volume":"86","author":"Hung","year":"2014","journal-title":"Eur J Med Chem"},{"key":"2026070713311404900_bib12","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/jm901647p","article-title":"Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists","volume":"53","author":"Katritch","year":"2010","journal-title":"J Med Chem"},{"key":"2026070713311404900_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbadis.2012.11.010","article-title":"ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells","volume":"1832","author":"Lazarini","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2026070713311404900_bib14","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1038\/s41467-021-24342-y","article-title":"The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells","volume":"12","author":"Leach","year":"2021","journal-title":"Nat Commun"},{"key":"2026070713311404900_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1039\/C3MD00290J","article-title":"The effect of a thieno[2,3-b]pyridine PLC-\u03b3 inhibitor on the proliferation, morphology, migration and cell cycle of breast cancer cells","volume":"5","author":"Leung","year":"2014","journal-title":"Med Chem Comm"},{"key":"2026070713311404900_bib16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bmc.2016.01.047","article-title":"Synthesis and cytotoxicity of thieno[2,3-b]quinoline-2-carboxamide and cycloalkyl[b]thieno[3,2-e]pyridine-2-carboxamide derivatives","volume":"24","author":"Leung","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2026070713311404900_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/DDDT.S121122","article-title":"Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-b]pyridine anticancer compound","volume":"11","author":"Mastelic","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2026070713311404900_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/146282","article-title":"Targeting the mitotic catastrophe signaling pathway in cancer","volume":"2015","author":"Mc Gee","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2026070713311404900_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/cancers11040568","article-title":"MSC.sTRAIL has better efficacy than MSC.FL-TRAIL and in combination with AKTi blocks pro-metastatic cytokine production in prostate cancer cells","volume":"11","author":"Mohr","year":"2019","journal-title":"Cancers"},{"key":"2026070713311404900_bib21","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1055\/s-0036-1588619","article-title":"Synthesis of 3-Amino-2-carboxamide Tetrahydropyrrolo[2,3-b]quinolines","volume":"27","author":"Pilkington","year":"2016","journal-title":"Synlett"},{"key":"2026070713311404900_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J Med Chem"},{"key":"2026070713311404900_bib23","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.bmc.2009.02.049","article-title":"The identification of novel PLC-gamma inhibitors using virtual high throughput screening","volume":"17","author":"Reynisson","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"2026070713311404900_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-016-0293-6","article-title":"Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative","volume":"16","author":"Reynisson","year":"2016","journal-title":"Cancer Cell Int"},{"key":"2026070713311404900_bib25","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1021\/jm400043d","article-title":"Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents","volume":"56","author":"Romagnoli","year":"2013","journal-title":"J Med Chem"},{"key":"2026070713311404900_bib26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2026070713311404900_bib27","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s10495-007-0144-y","article-title":"Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311","volume":"12","author":"Skwarska","year":"2007","journal-title":"Apoptosis"},{"key":"2026070713311404900_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-019-0448-6","article-title":"Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada","volume":"19","author":"Smith-Palmer","year":"2019","journal-title":"BMC Urol"},{"key":"2026070713311404900_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymeth.2016.09.016","article-title":"TrackMate: an open and extensible platform for single-particle tracking","volume":"115","author":"Tinevez","year":"2017","journal-title":"Methods"},{"key":"2026070713311404900_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/cdd.2008.47","article-title":"Death through a tragedy: mitotic catastrophe","volume":"15","author":"Vakifahmetoglu","year":"2008","journal-title":"Cell Death Differ"},{"key":"2026070713311404900_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bmcl.2016.12.009","article-title":"Synthesis and antiproliferative activity of 2-chlorophenyl carboxamide thienopyridines","volume":"27","author":"van Rensburg","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"2026070713311404900_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nchem.2381","article-title":"Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation","volume":"7","author":"Wang","year":"2015","journal-title":"Nat Chem"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/5\/1\/EO-24-0082.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/5\/1\/EO-24-0082.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0082\/196346\/eo-24-0082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0082\/196346\/eo-24-0082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:52:02Z","timestamp":1783446722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/5\/1\/e240082\/35037\/Thieno-2-3-b-pyridine-compounds-potently-inhibit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-24-0082","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"e240082"}}